Mumps infectious disease
disease diseaseOn this page
Also known as epidemic parotitismumpsMumps virus caused disease or disorderMumps virus disease or disorderMumps virus infectious disease
Summary
Mumps infectious disease (MONDO:0000989) is a disease and 68 clinical trials. Top therapeutic interventions include botulinum toxin type a, mumps virus vaccine live, and rubella virus vaccine live. A subtype of Paramyxoviridae infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 68
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | mumps infectious disease |
| Mondo ID | MONDO:0000989 |
| EFO | EFO:0007383 |
| MeSH | D009107, D019351 |
| DOID | DOID:10264 |
| ICD-10-CM | B26 |
| ICD-11 | 1208294714 |
| NCIT | C29888 |
| SNOMED CT | 36989005 |
| UMLS | C0026780 |
| MedGen | 44521 |
| Is cancer (heuristic) | no |
Also known as: epidemic parotitis · mumps · Mumps virus caused disease or disorder · Mumps virus disease or disorder · Mumps virus infectious disease
Disease family
An umbrella term covering 1 Mondo subtype.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › primary viral infectious disease › Mononegavirales infectious disease › Paramyxoviridae infectious disease › mumps infectious disease
Related subtypes (5): Avulavirus infectious disease, henipavirus infectious disease, morbillivirus infectious disease, respirovirus infectious disease, parainfluenza infectious disease
Subtypes (1): congenital mumps
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated or in trials for this disease
1 approved drug — disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Status |
|---|---|
| Mumps Virus, Live Attenuated | Approved (phase 4) |
1 drug in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.
| Drug | Highest phase |
|---|---|
| Mumps Virus Vaccine Live | Phase 3 |
Clinical trials & evidence
Clinical trials
Clinical trials: 68.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE3 | 32 |
| PHASE4 | 14 |
| Not specified | 12 |
| PHASE2 | 7 |
| PHASE1 | 2 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00126997 | PHASE4 | COMPLETED | Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases |
| NCT00313950 | PHASE4 | COMPLETED | Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine |
| NCT00326183 | PHASE4 | COMPLETED | Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) |
| NCT00388440 | PHASE4 | COMPLETED | Assess GSK Biologicals’ MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. |
| NCT00432731 | PHASE4 | COMPLETED | Safety Study of a Refrigerator-stable Formulation of VARIVAX® |
| NCT01777529 | PHASE4 | COMPLETED | Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations |
| NCT02325310 | PHASE4 | COMPLETED | Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR |
| NCT02880865 | PHASE4 | COMPLETED | Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine |
| NCT03160820 | PHASE4 | COMPLETED | Study on Immunization Schedule of Beijing Tiantan Biological’s Measles-mumps-rubella(MMR) Vaccine |
| NCT04364399 | PHASE4 | COMPLETED | Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine |
| NCT05279248 | PHASE4 | UNKNOWN | The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine |
| NCT05952505 | PHASE4 | UNKNOWN | Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines |
| NCT06208683 | PHASE4 | UNKNOWN | The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students |
| NCT06331702 | PHASE4 | COMPLETED | Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR) |
| NCT00092391 | PHASE3 | COMPLETED | A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED) |
| NCT00092430 | PHASE3 | COMPLETED | Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016) |
| NCT00109343 | PHASE3 | COMPLETED | V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019) |
| NCT00127010 | PHASE3 | COMPLETED | Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases |
| NCT00127023 | PHASE3 | COMPLETED | Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases |
| NCT00351923 | PHASE3 | COMPLETED | Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes |
| NCT00384397 | PHASE3 | COMPLETED | A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers |
| NCT00402831 | PHASE3 | COMPLETED | ProQuad® Intramuscular vs Subcutaneous |
| NCT00406211 | PHASE3 | COMPLETED | Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine |
| NCT00422292 | PHASE3 | COMPLETED | Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers |
| NCT00432042 | PHASE3 | COMPLETED | Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) |
| NCT00432523 | PHASE3 | COMPLETED | Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011) |
| NCT00483574 | PHASE3 | COMPLETED | Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers |
| NCT00560755 | PHASE3 | COMPLETED | Safety Study of ProQuad® rHA in Infants (V221-037) |
| NCT00566527 | PHASE3 | COMPLETED | Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) |
| NCT00751348 | PHASE3 | COMPLETED | Immunogenicity & Safety Study of GSK Biologicals’ Combined Measles-mumps-rubella-varicella Vaccine 208136 |
| NCT00839917 | PHASE3 | TERMINATED | A Study of ProQuad™ in Healthy Children in Korea (V221-023) |
| NCT00969436 | PHASE3 | COMPLETED | Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM |
| NCT00975507 | PHASE3 | COMPLETED | ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED) |
| NCT00984295 | PHASE3 | COMPLETED | Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines |
| NCT00985153 | PHASE3 | COMPLETED | Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED) |
| NCT00985166 | PHASE3 | COMPLETED | A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014) |
| NCT01188343 | PHASE3 | COMPLETED | Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers |
| NCT01506193 | PHASE3 | COMPLETED | Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children |
| NCT01536405 | PHASE3 | COMPLETED | Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) |
| NCT01681992 | PHASE3 | COMPLETED | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals’ Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| BOTULINUM TOXIN TYPE A | 4 | 1 |
| MUMPS VIRUS VACCINE LIVE | 3 | 2 |
| RUBELLA VIRUS VACCINE LIVE | 3 | 2 |